Q1 2026 Recap: Endocrinology News and Updates

Endocrinology is off to a stellar start in 2026, with a first quarter packed full of major FDA approvals and trial results. Orforglipron, now approved for type 2 diabetes (T2D), demonstrated some of its best trial performance in February, while the investigational triple agonist retatrutide demonstrated solid safety data in the same disease. Meanwhile, the US Food and Drug Administration (FDA) fired off a volley of approvals, covering the first once-weekly basal insulin for T2D, inhaled insulin powder for type 1 diabetes (T1D), and setmelanotide for the rare and previously poorly-managed acquired hypothalamic obesity.